Despite Vertex's Early Start, Competition Looms In CF
Executive Summary
Despite robust launch as expected, analyst anticipates some patients will exit Orkambi therapy due to lack of efficacy or noticeable symptom relief. Meanwhile, companies including Concert and Galapagos are positioning themselves to compete with CFTR-modulating therapies.